Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Guilpain, P.
Right arrow Articles by Guillevin, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guilpain, P.
Right arrow Articles by Guillevin, L.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 535-539
© 2002 British Society for Rheumatology

Original Papers

Churg–Strauss syndrome in two patients receiving montelukast

P. Guilpain, J.-F. Viallard1, P. Lagarde2, P. Cohen, M. Kambouchner3, J.-L. Pellegrin1 and L. Guillevin

Department of Internal Medicine, Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris, Université Paris-Nord UPRES EA 3409, 125 route de Stalingrad, 93009 Bobigny Cedex,
1 Department of Internal Medicine, Hôpital Haut-Lévêque, avenue de Magellan, 33604 Pessac Cedex,
2 Department of Internal Medicine, Centre Hospitalier de Lagny, Marne-la-Vallée, 31 avenue du Général-Leclerc, 77405 Lagny Cedex and
3 Department of Pathology, Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris, Université Paris-Nord, 125 route de Stalingrad, 93009 Bobigny Cedex, France

Objective. Churg–Strauss syndrome (CSS) has been described in association with the treatment of asthmatic patients with leukotriene receptor antagonist. The main mechanism proposed to explain this condition is the unmasking of CSS after the leukotriene receptor antagonist has allowed corticosteroid tapering. Other hypotheses might be proposed.

Methods. We describe two patients who developed CSS after starting treatment with montelukast, a new antileukotriene drug.

Results. Both patients presented with CSS after 4–5 months of treatment with montelukast. Neither patient received long-term systemic steroids for asthma, but both were on inhaled steroids. One patient had a myocardial involvement and experienced a stroke. Our two patients were treated with systemic steroids and cyclophosphamide.

Conclusions. CSS does not appear to relate to steroid tapering in our patients. The other hypotheses are a coincidence or a direct adverse effect of the antileukotriene. Long-term data on these drugs are lacking and leukotriene's role in vasculitis remains to be elucidated.

KEY WORDS: Churg–Strauss syndrome, Montelukast.

Correspondence to: L. Guillevin.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ThoraxHome page
R. Beasley, S. Bibby, and M. Weatherall
Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander?
Thorax, October 1, 2008; 63(10): 847 - 849.
[Full Text] [PDF]

Home page
 JAMAHome page
D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man
Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis
JAMA, July 21, 2004; 292(3): 367 - 376.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.